Munich, Germany-based life science-focused venture firm, TVM Capital Life Science Venture Capital, has achieved a US$50 million first closing of its maiden China-focused fund, according to a company announcement. The fund, named China BioPharma Capital I, will focus on investments in life science innovation in Western companies with the objective to obtain licenses for development […]

Visit for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.

Visit the original source and full text: China Money Network